Nuvalent Rings the Opening Bell

About This Event

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, James Porter, Ph.D., Chief Executive Officer of Nuvalent, rings the Opening Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore